These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

9890 related articles for article (PubMed ID: 1389515)

  • 1. Melphalan concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb perfusion.
    Scott RN; Blackie R; Kerr DJ; Hughes J; Burnside G; MacKie RM; Byrne DS; McKay AJ
    Eur J Cancer; 1992; 28A(11):1811-3. PubMed ID: 1389515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.
    Klaase JM; Kroon BB; Beijnen JH; van Slooten GW; van Dongen JA
    Br J Cancer; 1994 Jul; 70(1):151-3. PubMed ID: 8018528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of acute regional toxicity following isolated limb perfusion for melanoma.
    Thompson JF; Eksborg S; Kam PC; Ingvar C; Yau DF; Lai DT; Ramzan I
    Melanoma Res; 1996 Jun; 6(3):267-71. PubMed ID: 8819130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melphalan dosing regimens for management of recurrent melanoma by isolated limb perfusion: application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb.
    Wu ZY; Smithers BM; Roberts MS
    Melanoma Res; 1997 Jun; 7(3):252-64. PubMed ID: 9195565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
    Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
    J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can tissue drug concentrations be monitored by microdialysis during or after isolated limb perfusion for melanoma treatment?
    Wu ZY; Smithers BM; Anderson C; Roberts MS
    Melanoma Res; 2000 Feb; 10(1):47-54. PubMed ID: 10711640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.
    Bartlett DL; Ma G; Alexander HR; Libutti SK; Fraker DL
    Cancer; 1997 Dec; 80(11):2084-90. PubMed ID: 9392330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Melphalan pharmacokinetics during isolated limb regional perfusion in patients with skin melanoma and soft tissue sarcoma].
    Gafton GI; Senchik KY; Petrov VG; V V Semiglazov ; N V Tatyanicheva ; V G Bespalov ; Semiletova YV; Gafton IG; Zinoviev GV; Kireeva GS
    Vopr Onkol; 2015; 61(6):932-6. PubMed ID: 26995981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?
    Hoekstra HJ; Veerman K; van Ginkel RJ
    J Surg Oncol; 2014 Mar; 109(4):338-47. PubMed ID: 24403098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft.
    Wu ZY; Smithers BM; Parsons PG; Roberts MS
    Br J Cancer; 1997; 75(8):1160-6. PubMed ID: 9099965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics.
    Benckhuijsen C; Kroon BB; van Geel AN; Wieberdink J
    Eur J Surg Oncol; 1988 Apr; 14(2):157-63. PubMed ID: 3360157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma.
    Thompson JF; Lai DT; Ingvar C; Kam PC
    Melanoma Res; 1994 Mar; 4 Suppl 1():45-50. PubMed ID: 8038596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.
    Scott RN; Kerr DJ; Blackie R; Hughes J; Burnside G; MacKie RM; Byrne DS; McKay AJ
    Br J Cancer; 1992 Jul; 66(1):159-66. PubMed ID: 1637666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma.
    Smith HG; Cartwright J; Wilkinson MJ; Strauss DC; Thomas JM; Hayes AJ
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S356-61. PubMed ID: 26350373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics & drug resistance of melphalan in regional chemotherapy: ILP versus ILI.
    Padussis JC; Steerman SN; Tyler DS; Mosca PJ
    Int J Hyperthermia; 2008 May; 24(3):239-49. PubMed ID: 18393002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.
    Koops HS; Vaglini M; Suciu S; Kroon BB; Thompson JF; Göhl J; Eggermont AM; Di Filippo F; Krementz ET; Ruiter D; Lejeune FJ
    J Clin Oncol; 1998 Sep; 16(9):2906-12. PubMed ID: 9738557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolated limb perfusion for unresectable melanoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
    Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 495.